Bristol's Blenoxane indicated for prevention of recurrent pleural effusions and treatment of MPEs.
Executive Summary
BRISTOL BLENOXANE INDICATED FOR PREVENTION OF RECURRENT EFFUSIONS as well as treatment of pleural effusions associated with cancers, final product labeling states. "Blenoxane is effective as a sclerosing agent for the treatment of malignant pleural effusions and prevention of recurrent pleural effusions," the label says. Blenoxane (bleomycin) was approved for the supplemental indication Feb. 20 based on a literature review ("The Pink Sheet" Feb. 26, T&G-3).